Targets › CA9
8 programs from 7 companies in 9 trials: 4 Phase 2, 4 Phase 1, 1 Phase 3; Oncology, Other; next expected readout Dec 2026.
Catalyzes the interconversion between carbon dioxide and water and the dissociated ions of carbonic acid (i.e. bicarbonate and hydrogen ions). (UniProt, Q16790)
Open in Phaseline: the race on CA9, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Telix Pharmaceuticals (Innovations) | Girentuximab (TLX250) Carbonic anhydrase IX other | CA9 | Phase 3 | Clear Cell Renal Cell Carcinoma | – |
| IRCCS Ospedale San Raffaele | [89Zr]Zr-DFO-Girentuximab Carbonic anhydrase IX (CAIX) targeting radiopharmaceutical; girentuximab is an anti-CAIX m | CA9 | Phase 2 | VHL - Von Hippel-Lindau Syndrome | Dec 2026 |
| Memorial Sloan Kettering Cancer Center | 177Lu-labeled-girentuximab Radiolabeled anti-CA9 monoclonal antibody for targeted radionuclide therapy | CA9 | Phase 2 | Clear Cell Renal Cell Carcinoma | Mar 2027 |
| Peking Union Medical College Hospital | 68Ga-NY104 PET/CT CAIX-targeted PET tracer | CA9 | Phase 2 | Clear Cell Renal Cell Carcinoma | Sep 2028 |
| Beijing Biotech | EB-701/CA9-NK Dual-target CD70/CAIX CAR-NK cells | CD70, CA9 | Phase 1 | Advanced or Metastatic Clear Cell Renal Cell Carcinoma | Apr 2027 |
| M.D. Anderson Cancer Center | 177Lu girentuximab Radiolabeled anti-CA9 monoclonal antibody | CA9 | Phase 1 | Advanced Cancer | Oct 2027 |
| PeptiDream | PD-32766D (Copper-64 [64Cu] labeled peptide) 64Cu-labeled peptide targeting carbonic anhydrase IX (CA9) for PET/CT imaging | CA9 | Phase 1 | Clear Cell Renal Cell Carcinoma | May 2029 |
| PeptiDream | PD-32766T (Actinium-225 [225Ac] labeled peptide) 225Ac-labeled peptide targeting carbonic anhydrase IX (CA9) for targeted alpha particle th | CA9 | Phase 1 | Clear Cell Renal Cell Carcinoma | May 2029 |
Clear Cell Renal Cell Carcinoma (6) Advanced Cancer (1) Advanced or Metastatic Clear Cell Renal Cell Carcinoma (1) VHL - Von Hippel-Lindau Syndrome (1)
protein or peptide (3), mixed (3), antibody (2)
PeptiDream (2) Telix Pharmaceuticals (Innovations) (1) M.D. Anderson Cancer Center (1) Memorial Sloan Kettering Cancer Center (1) Beijing Biotech (1) IRCCS Ospedale San Raffaele (1) Peking Union Medical College Hospital (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.